Curated News
By: NewsRamp Editorial Staff
August 03, 2026
Tonix Pharma Gets FDA Nod for Phase 2 Lyme Vaccine Study
TLDR
- Tonix Pharmaceuticals gains FDA support for its Lyme disease prevention trial, positioning it ahead in a high-demand market.
- Tonix's TNX-4800 Phase 2 trial will enroll 3,300 adults over two seasons with two injections three months apart.
- Tonix's potential Lyme disease prevention could protect thousands from a debilitating illness, improving public health.
- TNX-4800 is a long-acting antibody, not a vaccine, offering a novel approach to seasonal Lyme disease prevention.
Impact - Why it Matters
This news matters because it signals progress in the fight against Lyme disease, a growing public health concern in the U.S. With the FDA's support, Tonix is moving closer to a potential preventative treatment that could offer six months of protection per dose, addressing a significant unmet medical need. If successful, TNX-4800 could become a seasonal immunopreventative, reducing the burden of Lyme disease for millions at risk. For investors, this development also highlights Tonix's pipeline strength beyond its marketed products, potentially impacting the company's valuation and future revenue streams.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) has received encouraging feedback from the U.S. Food and Drug Administration (FDA) in a Type C meeting, supporting the company's plans for an adaptive Phase 2 field study of TNX-4800, its long-acting anti-OspA monoclonal antibody candidate designed to prevent Lyme disease. The planned randomized, placebo-controlled study is expected to enroll approximately 3,300 adults over two Lyme disease seasons, with the goal of evaluating prevention through six months after dosing. Manufacturing of the investigational product is on track for delivery to study sites in the first quarter of 2027. TNX-4800 is being developed as a seasonal immunopreventative administered as two subcutaneous injections three months apart, offering potential protection throughout the U.S. Lyme disease season.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in over 15 years. The company's CNS portfolio also includes acute migraine products Zembrace® SymTouch® and Tosymra®, and it is advancing TNX-2900 for Prader-Willi syndrome. In immunology, Tonix is developing TNX-4800 for Lyme disease prophylaxis and TNX-1500 for prevention of kidney transplant rejection. The company's CNS commercial infrastructure supports its marketed products, and it is maximizing the science behind TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder.
The news was highlighted by TinyGems, a specialized communications platform focusing on innovative small-cap and mid-cap companies, which is part of the Dynamic Brand Portfolio @ IBN. TinyGems provides access to a vast network of wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, enhanced press release distribution, social media distribution, and tailored corporate communications solutions. For more details, visit the full press release at https://ibn.fm/pe0eP and the company's newsroom at https://ibn.fm/TNXP. To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192. Please see full terms of use and disclaimers on the TinyGems website.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharma Gets FDA Nod for Phase 2 Lyme Vaccine Study
